Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Exelixis Inc (EXEL)  
$36.65 0.15 (0.41%) as of 4:30 Fri 3/14


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 310,240,000
Market Cap: 11.37(B)
Last Volume: 1,994,274 Avg Vol: 2,362,196
52 Week Range: $20.34 - $39.155
Level I Sector: Industrials
Level II Sector: Diversified Services
Level III Sector: Research Services

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Exelixis is an oncology-focused biotechnology company that engages in the discovery, development and commercialization of new medicines for cancers. Co.'s products include: CABOMETYX® (cabozantinib) tablets approved for renal cell carcinoma, and for previously treated hepatocellular carcinoma; and COMETRIQ® (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The other products are: COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 425,000 735,409
Total Buy Value $0 $0 $8,733,955 $15,268,727
Total People Bought 0 0 1 1
Total Buy Transactions 0 0 2 4
Total Shares Sold 303,926 643,662 1,129,338 1,681,109
Total Sell Value $11,139,944 $22,648,413 $35,001,763 $46,750,740
Total People Sold 10 11 13 14
Total Sell Transactions 12 21 35 47
End Date 2024-12-15 2024-09-13 2024-03-15 2023-03-16

   
Records found: 1076
  Page 1 of 44  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Haley Patrick J. EVP, Commercial   •       –      –    2025-03-03 4 AS $38.80 $388,000 D/D (10,000) 341,028 -5%     
   Wyszomierski Jack L Director   –       •      –    2025-02-28 4 AS $37.80 $331,430 D/D (8,768) 356,605 -5%     
   Wyszomierski Jack L Director   –       •      –    2025-02-28 4 OE $20.50 $325,417 D/D 15,874 365,373     -
   Smith Julie Director   –       •      –    2025-02-28 4 S $37.62 $725,840 D/D (19,294) 10,778 5%     
   Smith Julie Director   –       •      –    2025-02-28 4 OE $19.77 $381,442 D/D 19,294 30,072     -
   Smith Julie Director   –       •      –    2025-02-27 4 S $38.13 $2,078,619 D/D (54,514) 10,778 2%     
   Smith Julie Director   –       •      –    2025-02-27 4 OE $19.77 $1,100,494 D/D 54,514 65,292     -
   Peterson Amy C. EVP Prod Dev & Med Aff & CMO   •       –      –    2025-02-26 4 A $0.00 $0 D/D 52,192 347,089     -
   Haley Patrick J. EVP, Commercial   •       –      –    2025-02-26 4 A $0.00 $0 D/D 47,718 351,028     -
   Senner Christopher J. EVP and CFO   •       –      –    2025-02-26 4 A $0.00 $0 D/D 59,648 839,255     -
   Morrissey Michael M President and CEO   •       •      –    2025-02-26 4 A $0.00 $0 D/D 184,909 1,033,290     -
   Aftab Dana CSO/EVP Disc & Trans Research   •       –      –    2025-02-26 4 A $0.00 $0 D/D 49,209 561,117     -
   Hessekiel Jeffrey EVP & General Counsel   •       –      –    2025-02-26 4 A $0.00 $0 D/D 52,192 597,608     -
   Oliver Bob Director   –       •      –    2025-02-25 4 S $37.25 $694,601 D/D (18,647) 33,514 0%     
   Oliver Bob Director   –       •      –    2025-02-25 4 OE $19.28 $292,034 D/D 15,147 52,161     -
   Haley Patrick J. EVP, Commercial   •       –      –    2025-02-24 4 S $36.98 $1,946,479 D/D (52,636) 303,310 1%     
   Morrissey Michael M President and CEO   •       •      –    2025-02-24 4 GA $0.00 $0 I/I 177,985 1,764,985     -
   Morrissey Michael M President and CEO   •       •      –    2025-02-24 4 GD $0.00 $0 D/D 177,985 848,381     -
   Senner Christopher J. EVP and CFO   •       –      –    2025-02-24 4 S $36.14 $1,059,408 D/D (29,314) 779,607 1%     
   Senner Christopher J. EVP and CFO   •       –      –    2025-02-24 4 OE $18.80 $551,103 D/D 29,314 808,921     -
   Aftab Dana CSO/EVP Disc & Trans Research   •       –      –    2025-02-24 4 S $36.75 $991,772 D/D (26,987) 511,908 1%     
   Aftab Dana CSO/EVP Disc & Trans Research   •       –      –    2025-02-15 4 D $35.00 $1,006,180 D/D (28,748) 538,895     -
   Senner Christopher J. EVP and CFO   •       –      –    2025-02-15 4 D $35.00 $755,685 D/D (21,591) 779,607     -
   Morrissey Michael M President and CEO   •       •      –    2025-02-15 4 D $35.00 $2,224,950 D/D (63,570) 1,026,366     -
   Haley Patrick J. EVP, Commercial   •       –      –    2025-02-15 4 D $35.00 $661,710 D/D (18,906) 355,946     -
  1076 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 44
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2025 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us